Customizable Polymeric Nanoparticle Materials Optimized on Hypoxic Cells Facilitate mRNA Expression in the Lungs In Vivo
Advanced Healthcare Materials · 2025-07 · 14 (17)
DOI: 10.1002/adhm.202500245 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 27.05.2025. Verfasst von Palas Balakdas Tiwade und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, N…. Hauptthemen laut MEDLINE: RNA, Messenger, Nanoparticles, Lung, Polymers. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIH National Institute of Biomedical Imaging and Bioengineering, NC Translational and Clinical Sciences, NCATS NIH HHS.
Abstract (Originalsprache)
mRNA therapy has shown great potential in treating lung diseases by enabling transient protein expression without permanently altering the genome. Despite advancements, most mRNA delivery systems, such as lipid nanoparticles and polymeric nanoparticles, predominantly express mRNA in the liver, limiting their effectiveness for extrahepatic organs like the lungs. Furthermore, hypoxia, a common feature of many pulmonary diseases, significantly reduces mRNA translation and protein synthesis, impacting therapeutic outcomes. In this study, we present a Tunable Lung Expressing Nanoparticle Platform ( TULEP ) designed to enhance mRNA delivery to the lungs and improve protein expression under hypoxic conditions. Our approach involved the combinatorial synthesis of polymers with varied hydrocarbon tail lengths and reaction equivalencies, followed by formulation into mRNA‐loaded nanoparticles. These nanoparticles were characterized for size, charge, and mRNA encapsulation efficiency, and mechanistic and efficacy studies under normoxia and hypoxia were performed in vitro. In vivo studies demonstrated that the top‐performing TULEP s improve mRNA‐encoded protein expression in the lungs in a well‐tolerated fashion as suggested by weight loss, blood paneling, and histological analyses. Taken together, these results highlight TULEP s as a viable platform for tunable expression of mRNA in the lungs and under hypoxia, highlighting their potential for long‐term disease therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Pharmacoengineering and Molecular Pharmaceutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
- Department of Pharmacology, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, 27599, USA.
ORCID-Profile: Owen S Fenton
Förderung
- NIH National Institute of Biomedical Imaging and Bioengineering
- NC Translational and Clinical Sciences
- NCATS NIH HHS
- NICHD NIH HHS
- NIH HHS
- NINDS NIH HHS
- NIGMS NIH HHS
- National Cancer Institute of the National Institutes of Health
Zitieren
APA
Tiwade, P. B., Fung, V., Ma, Y., VanKeulen-Miller, R., Narasipura, E. A., & Fenton, O. S. (2025). Customizable Polymeric Nanoparticle Materials Optimized on Hypoxic Cells Facilitate mRNA Expression in the Lungs In Vivo. Advanced Healthcare Materials, 14(17). https://doi.org/10.1002/adhm.202500245
Vancouver
Tiwade PB, Fung V, Ma Y, VanKeulen-Miller R, Narasipura EA, Fenton OS. Customizable Polymeric Nanoparticle Materials Optimized on Hypoxic Cells Facilitate mRNA Expression in the Lungs In Vivo. Advanced Healthcare Materials. 2025;14(17). doi:10.1002/adhm.202500245
BibTeX
@article{Tiwade2025,
author = {Tiwade, Palas Balakdas and Fung, Vincent and Ma, Yutian and VanKeulen-Miller, Rachel and Narasipura, Eshan A and Fenton, Owen S},
title = {Customizable Polymeric Nanoparticle Materials Optimized on Hypoxic Cells Facilitate mRNA Expression in the Lungs In Vivo},
journal = {Advanced Healthcare Materials},
year = {2025},
volume = {14},
number = {17},
doi = {10.1002/adhm.202500245}
}
EUVIMED